Research Keyword: azole antifungals

Establishment of epidemiological cutoff values for Fonsecaea pedrosoi, the primary etiologic agent of chromoblastomycosis, and eight antifungal medications

mycolabadmin

Chromoblastomycosis is a serious fungal skin infection caused by a fungus called Fonsecaea pedrosoi, particularly affecting people in tropical regions and those in poverty. Researchers from multiple countries tested 148 samples of this fungus against eight different antifungal medications to determine how well each drug works. They established baseline measurements that doctors can use to determine if a patient’s fungal infection might not respond well to standard treatments, helping guide better treatment decisions.

Read More »

The efficacy of luliconazole and caspofungin on planktonic and biofilm of Candida albicans from different sources

mycolabadmin

Candida albicans, a common yeast infection organism, can form tough protective structures called biofilms that resist antifungal medications. This study tested two antifungal drugs (luliconazole and caspofungin) against Candida in both regular form and biofilm form. The results showed that while these drugs work well against regular Candida cells, they are much less effective against biofilms, which require 15-171 times higher doses to be inhibited. The strongest biofilms came from vaginal infections, suggesting that different infection types may require different treatment approaches.

Read More »

Retrospective Analysis on the Efficacy and Adverse Effects of Antifungal Prophylaxis in Patients with Peritoneal Dialysis-Associated Peritonitis

mycolabadmin

This study examined whether giving antifungal medications to peritoneal dialysis patients with infections could prevent fungal peritonitis. The researchers found that patients receiving antifungal prophylaxis actually had higher rates of secondary fungal infections compared to those without it. Additionally, fluconazole treatment was associated with dangerous changes in heart electrical activity, suggesting potential cardiac risks.

Read More »

Safety and Efficacy of a 48-Month Efinaconazole 10% Solution Treatment/Maintenance Regimen: 24-Month Daily Use Followed by 24-Month Intermittent Use

mycolabadmin

Researchers studied a 4-year treatment plan for toenail fungal infections using efinaconazole, an antifungal solution applied daily for 2 years, then 2-3 times weekly for another 2 years. The treatment was safe and effective, with all patients who achieved a cure maintaining it through the maintenance phase, and even some non-cured patients improving further. The study included many elderly patients, showing the treatment is safe across all age groups and could help prevent infection relapse.

Read More »
Scroll to Top